Compare Emerson Electric Co. (EMR) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Enveric Biosciences Inc — how do they compare? Emerson Electric Co. trades at $163.98 (market cap $88.53B), while Enveric Biosciences Inc trades at $1.45 (market cap $6.20M). The key difference: Emerson Electric Co. is far larger — about 14279× Enveric Biosciences Inc's market cap, and Emerson Electric Co. pays a 1.4% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| EMR | ENVB | |
|---|---|---|
Market Cap | $88.53B | $6.20M |
Sector | Industrials | Health |
52-Week High | $164.38 | $17.40 |
52-Week Low | $123.30 | $1.27 |
Enterprise Value | $99.60B | $1.30M |
Dividend Yield | 1.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $158.26, up 0.86% on the day, with a bullish technical signal and strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows robust fundamentals, including a 13.83% net income margin and consistent revenue growth, supported by recent acquisitions like Glue Inc. to enhance AI capabilities. Analyst consensus is positive, with a $171.33 price target indicating potential upside from current levels.
Outlook remains favorable due to organic growth and raised 2026 guidance, but risks include valuation concerns with a P/E of 34.63 and macroeconomic pressures. Investment opportunity hinges on execution in automation and AI segments, while investors should monitor debt levels and competitive dynamics in the industrial sector.
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
